Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com.
View Top Employees from Lineage Cell TherapeuticsWebsite | http://www.lineagecell.com |
Ticker | BTX |
Revenue | $17 million |
Employees | 39 (39 on RocketReach) |
Founded | 1990 |
Address | 2173 Salk Avenue Suite 200, Carlsbad, California 92008, US |
Phone | (510) 521-3390 |
Fax | (510) 521-3389 |
Industry | Biotechnology Research, Drug Manufacturing & Research, Pharmaceuticals, Healthcare |
Web Rank | 4 Million |
Keywords | Biotime, Voluven, Agex Purestem, Biotime Ha And, Molecular Weight Hystem Glycosil Biotime |
Competitors | Athersys, Mesoblast Limited, Osiris Therapeutics, Tessa Therapeutics Ltd, ViaCyte |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325414 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies |
Looking for a particular Lineage Cell Therapeutics employee's phone or email?
The Lineage Cell Therapeutics annual revenue was $17 million in 2024.
Jill Howe is the CFO of Lineage Cell Therapeutics.
39 people are employed at Lineage Cell Therapeutics.
Lineage Cell Therapeutics is based in Carlsbad, California.
The NAICS codes for Lineage Cell Therapeutics are [32, 3254, 325414, 32541, 325].
The SIC codes for Lineage Cell Therapeutics are [283, 28].